Differential chemoprotection against acetaminophen-induced hepatotoxicity by latentiated L-cysteines.
Novel thiazolidine prodrugs were prepared by the condensation of L-cysteine with aldose disaccharides. Using a disaccharide in prodrug construction allows for a terminal cyclic sugar moiety to be present on the prodrug, which may allow the delivery of the agent to specific receptors, such as the asialoglycoprotein receptor (ASGPR) of hepatocytes, that require specific structural motifs for recognition. Three L-cysteine prodrugs were synthesized with a pendant cyclic galactose moiety; two related glucose-bearing prodrugs were synthesized for comparison. The prodrugs were designed to release L-cysteine, which is then available to support glutathione (GSH) biosynthesis and provide cytoprotection against a variety of toxic insults. Protection studies in Swiss-Webster mice used acetaminophen (575 mg/kg), a well-documented hepatotoxin which depletes GSH at overdose. Three prodrugs performed exceptionally well against acetaminophen-induced hepatotoxicity, as measured by increased survival and improved histological profiles of liver tissue after 48 h. In further experimentation, two of the disaccharide-based prodrugs, prepared from alpha- and beta-lactose, were compared with the monosaccharide-based compound prepared from ribose. Co-administration of the selected prodrugs with a 400 mg/kg dose of acetaminophen to Swiss-Webster mice prevented the short-term depletion in hepatic GSH and also reduced hepatotoxicity as determined by histological damage and serum levels of alanine aminotransferase. A single dose of the prodrugs alone had no effect on hepatic drug metabolizing enzymes [glutathione S-transferase (GST), NAD(P)H:quinone oxidoreductase (QOR), UDP-glucuronosyltransferase (UGT), and cytochrome P450], but, concordant with the reduction of hepatotoxicity, the latentiated forms prevented the significant elevation in QOR activity and mRNA and GST mRNA elicited by acetaminophen itself. GST activity, UGT activity and mRNA, and cytochrome P450 concentration were all unaffected by acetaminophen or the prodrugs. These studies identified novel L-cysteine prodrugs with potentially useful hepatoprotective activity. However, no structure-activity relationships were obvious. In addition, the occurrence of targeted delivery to hepatocytes remains ambiguous.
Roberts
J C
JC
Department of Medicinal Chemistry, University of Utah, Salt Lake City, Utah 84112, Department of Anatomical Pathology, Veterans Affairs Medical Center, Salt Lake City, Utah 84148. jroberts@deans.pharm.utah.edu
Phaneuf
H L
HL
Szakacs
J G
JG
Zera
R T
RT
Lamb
J G
JG
Franklin
M R
MR
D000082:Acetaminophen / Q000037:antagonists & inhibitors* / Q000633:toxicity; D000818:Animals; D056486:Chemical and Drug Induced Liver Injury / Q000201:enzymology / Q000517:prevention & control*; D003545:Cysteine / Q000031:analogs & derivatives* / Q000494:pharmacology*; D004187:Disaccharides / Q000737:chemistry; D005978:Glutathione / Q000378:metabolism; D051379:Mice; D011355:Prodrugs / Q000737:chemistry; D011808:Quinone Reductases / Q000378:metabolism; D012333:RNA, Messenger / Q000096:biosynthesis
D004187:Disaccharides; D011355:Prodrugs; D012333:RNA, Messenger; D000082:Acetaminophen; D011808:Quinone Reductases; D005978:Glutathione; D003545:Cysteine